National Cancer Board starts work on Cancer Plan

If you hear the word 'board' and expect paperwork rather than change, you are not alone. But England’s reformed National Cancer Board matters because it has been set up to do a very practical job: keep checking whether the country’s cancer promises are becoming real care for real people. According to the Department of Health and Social Care, the board met for the first time to scrutinise progress on faster diagnosis, treatment, quality of life and patient experience. In the government announcement, Health and Social Care Secretary Yvette Cooper presented this as part of a wider push for earlier diagnosis, more advanced treatment and better outcomes.

The board sits alongside the National Cancer Plan, published in February 2026. That plan contains more than 100 commitments and one big test for the decade ahead: by 2035, the government wants three in four people diagnosed with cancer to be cancer-free or living well five years after diagnosis. For us as readers, this is the part worth holding on to. A national plan is not only a document filled with aims. It is a promise that can be checked. Are more people being diagnosed early? Are waiting times falling? Are people living better during and after treatment? Those are the questions the board is supposed to keep asking.

The new body is not there to run hospitals day by day. Its role is to scrutinise, spot where delivery is stalling and advise ministers on where action is needed. It will meet every quarter, publish an annual assessment of progress and carry out a fuller review after three years. That structure matters because accountability is often where health plans become vague. The independent co-chair is Anita Charlesworth, working alongside Mark Cubbon from NHS England and the Department of Health and Social Care. If the board works as intended, patients and the public should be able to see not just the promises, but the scorecard as well.

One of the clearest signals in the announcement is about whose voices will not be left at the edge of the conversation. Dr Rob Metcalf will lead on rare cancers, including brain tumours. Dr Dianne Addei will lead on inequalities. Ashley Ball-Gamble will lead on children and young people’s cancers. **What this means:** these are not side issues. Rare cancers can be harder to diagnose, harder to research and easier for a system to overlook because the numbers are smaller. Children and young people often need support that goes beyond standard adult services, from education and mental health to fertility and family life. An inequalities lead matters because cancer outcomes are not shaped by biology alone; they are also shaped by postcode, poverty, access and whether the system hears you in time.

The government says cancer performance is improving, with all three cancer standards better than a year ago. It also says around 250,000 more people over the last year were either diagnosed on time or had cancer ruled out, compared with the year before the election. That is welcome, but it is not the whole story. National improvement can still sit alongside local delay. Better averages can still hide who is waiting longest or who is least likely to get specialist care. This is why a board like this should do more than applaud progress; it should keep pressure on the places where the figures still do not translate into a fair experience.

The National Cancer Plan already reaches into everyday care. The government says it is expanding lung cancer screening and Community Diagnostic Centres, improving access to advanced treatments and research, and strengthening support for children and young people, people living with and beyond cancer, and people with rare cancers. Ministers also point to prevention work through the Tobacco and Vapes Act, targeted screening programmes and wider access to advanced radiotherapy. If you are trying to make sense of that range, think of cancer care as a chain. Prevention sits at one end, diagnosis and treatment sit in the middle, and recovery and long-term support sit at the other. The plan only succeeds if the whole chain holds.

Charities have welcomed the board, but their backing comes with an important message. Cancer Research UK has said lasting change needs strong leadership and clear accountability. Macmillan Cancer Support has pointed to the importance of putting inequalities at the centre from the start. Cancer52, Young Lives vs Cancer and CCLG have all stressed that people with rare cancers, and children and young people with cancer, need sustained attention rather than a brief mention in a strategy document. So here is the plain-language test. A first meeting is not the same thing as better care. What matters now is whether quarterly scrutiny leads to shorter waits, earlier diagnoses, better treatment access and stronger support that patients can actually feel. That is what this board exists to prove.